Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial.
Clinical Added Value
minor
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion.
Listen
